Penumbra Inc. Agrees to Be Acquired by Boston Scientific for $374.00 Cash and Stock per Share

summarizeSummary

Penumbra Inc. has entered into a definitive merger agreement to be acquired by Boston Scientific Corporation in a transaction valued at $374.00 per share, comprising both cash and stock consideration. This acquisition represents a significant premium for Penumbra shareholders and will result in Penumbra becoming a wholly-owned subsidiary of Boston Scientific.

check_boxKey Events

• Definitive Merger Agreement

  Penumbra Inc. has entered into an Agreement and Plan of Merger to be acquired by Boston Scientific Corporation.

• Mixed Cash and Stock Consideration

  Penumbra shareholders will receive $374.00 in cash or 3.8721 Boston Scientific shares per Penumbra share, subject to proration (73.26% cash, 26.74% stock).

• Significant Shareholder Premium

  The cash consideration of $374.00 per share represents a premium over Penumbra's current trading price of $354.66 and its 52-week high of $355.53.

• Equity Award Conversion

  Outstanding Company Options and Restricted Stock Units (RSUs) will be converted into a mix of cash and Boston Scientific shares based on specified formulas.

auto_awesomeAnalysis

Penumbra Inc. has announced a definitive merger agreement to be acquired by Boston Scientific Corporation, a major development for its shareholders. The transaction offers Penumbra shareholders a choice of $374.00 in cash or 3.8721 shares of Boston Scientific common stock for each Penumbra share they own, subject to a proration mechanism ensuring approximately 73.26% cash and 26.74% stock. This offer price represents a notable premium over Penumbra's current stock price and its 52-week high, indicating strong value for existing investors. The acquisition is subject to customary closing conditions, including Penumbra shareholder approval and various regulatory clearances, such as those under the HSR Act. The agreement also features substantial termination fees, with Penumbra potentially paying $525 million and Boston Scientific potentially paying $900 million under specific circumstances, particularly related to regulatory non-approval. This structure underscores the strategic importance of the deal for Boston Scientific and provides a significant financial outcome for Penumbra's investors.